Financhill
Back

Kobayashi Pharmaceutical Quote, Financials, Valuation and Earnings

Better Than Oil Stocks

CLICK HERE TO FIND OUT MORE
Sell
45

KBYPF
Kobayashi Pharmaceutical

Last Price:
37.43
Seasonality Move:
-2.19%

7 Day Trial

ALL ACCESS PASS

$ 7

Zero Day Options Trade LIVE Tuesday at 2 p.m. ET!

Discover The Zero Day Loophole (BEFORE Tues at 2 p.m. ET!)

Kobayashi Pharmaceutical Price Quote

$37.43

Kobayashi Pharmaceutical Key Stats

Sell
45
Kobayashi Pharmaceutical (KBYPF) is a Sell

Day range:
$37.43 - $37.43
52-week range:
$31.81 - $38.93
Dividend yield:
1.81%
P/E ratio:
19.58
P/S ratio:
2.47
P/B ratio:
2.14%

Volume:
0
Avg. volume:
23
1-year change:
0%
Market cap:
$2.8B
Revenue:
$1.2B
EPS:
$0.92

How Much Does Kobayashi Pharmaceutical Make?

Is Kobayashi Pharmaceutical Growing As A Company?

Kobayashi Pharmaceutical Stock Price Performance

What Is Kobayashi Pharmaceutical 52-Week High & Low?

Kobayashi Pharmaceutical Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Kobayashi Pharmaceutical?

Is Kobayashi Pharmaceutical Cash Flow Positive?

Data Unavailable

Kobayashi Pharmaceutical Return On Invested Capital

  • Is Management Doing A Good Job?
    KBYPF return on invested capital is 4.95%
  • What Is Kobayashi Pharmaceutical Return On Assets?
    ROA measures how assets are converting to revenues and is 3.88%
  • What Is KBYPF Return On Equity?
    ROE is a measure of profitability and is 6.81%

Kobayashi Pharmaceutical Earnings Date & Stock Price

Kobayashi Pharmaceutical Competitors

Kobayashi Pharmaceutical Dividend Yield

Kobayashi Pharmaceutical Analyst Estimates

YoY Growth Past Surprise
EPS: -49.02% 0%
Revenue: -11.66% 0%

Analyst Recommendations

Buy Recommendations: 0
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 0.00
Downside from Last Price: -100%

Major Shareholders

  • How many KBYPF shares are owned by institutional investors?
    10.1M KBYPF shares are owned by institutional investors
  • How many KBYPF shares are owned by insiders?
    0 KBYPF shares are owned by insiders